Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE; DURATION-2 Study Group.

Lancet. 2010 Aug 7;376(9739):431-9. doi: 10.1016/S0140-6736(10)60590-9. Epub 2010 Jun 26.

PMID:
20580422
2.

Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.

Lo C, Jun M, Badve SV, Pilmore H, White SL, Hawley C, Cass A, Perkovic V, Zoungas S.

Cochrane Database Syst Rev. 2017 Feb 27;2:CD009966. doi: 10.1002/14651858.CD009966.pub2. Review.

PMID:
28238223
3.

[Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].

Lecube A, Bueno M, Suárez X.

Med Clin (Barc). 2014 Sep;143 Suppl 2:23-7. doi: 10.1016/S0025-7753(14)70105-8. Epub 2014 Oct 15. Review. Spanish.

PMID:
25437462
4.

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

Karagiannis T, Liakos A, Bekiari E, Athanasiadou E, Paschos P, Vasilakou D, Mainou M, Rika M, Boura P, Matthews DR, Tsapas A.

Diabetes Obes Metab. 2015 Nov;17(11):1065-74. doi: 10.1111/dom.12541. Epub 2015 Sep 23. Review.

PMID:
26395850
5.

Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.

Xue X, Ren Z, Zhang A, Yang Q, Zhang W, Liu F.

Int J Clin Pract. 2016 Aug;70(8):649-56. doi: 10.1111/ijcp.12847. Epub 2016 Jul 25. Review.

PMID:
27456750
6.

Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.

Thompson AM, Trujillo JM.

Ann Pharmacother. 2015 Mar;49(3):351-9. doi: 10.1177/1060028014564180. Epub 2015 Jan 6. Review.

PMID:
25565404
7.

Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.

Zaccardi F, Htike ZZ, Webb DR, Khunti K, Davies MJ.

Ann Intern Med. 2016 Jan 19;164(2):102-13. doi: 10.7326/M15-1432. Epub 2015 Dec 8. Review.

PMID:
26642233
8.

Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.

Syed YY, McCormack PL.

Drugs. 2015 Jul;75(10):1141-52. doi: 10.1007/s40265-015-0420-z. Review.

PMID:
26071140
10.

Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies.

Wang T, Gou Z, Wang F, Ma M, Zhai SD.

PLoS One. 2014 Aug 4;9(8):e103798. doi: 10.1371/journal.pone.0103798. eCollection 2014. Review.

11.

The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review.

Ojo O.

Int J Environ Res Public Health. 2016 Sep 23;13(10). pii: E941. doi: 10.3390/ijerph13100941. Review.

12.

Dulaglutide: A Review in Type 2 Diabetes.

Burness CB, Scott LJ.

BioDrugs. 2015 Dec;29(6):407-18. doi: 10.1007/s40259-015-0143-4. Review.

PMID:
26423061
13.

Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review.

Zhang L, Zhang M, Zhang Y, Tong N.

Sci Rep. 2016 Jan 8;6:18904. doi: 10.1038/srep18904. Review.

14.

Once-weekly exenatide as a treatment for Type 2 diabetes.

Schauerhamer MB, Gurgle H, McAdam-Marx C.

Expert Rev Cardiovasc Ther. 2015 Jun;13(6):611-26. doi: 10.1586/14779072.2015.1038242. Review.

PMID:
26000560
15.

Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes.

Brunton S, Davidson JA.

Clin Ther. 2016 Mar;38(3):582-94. doi: 10.1016/j.clinthera.2016.01.014. Epub 2016 Feb 28. Review.

PMID:
26926319
16.

Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.

Scheen AJ.

Expert Opin Drug Metab Toxicol. 2015 Jun;11(6):1005-20. doi: 10.1517/17425255.2015.1041499. Epub 2015 May 2. Review.

PMID:
25936384
17.

Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes.

Saulsberry WJ, Coleman CI, Mearns ES, Zaccaro E, Doleh Y, Sobieraj DM.

Int J Clin Pract. 2015 Nov;69(11):1221-35. doi: 10.1111/ijcp.12698. Epub 2015 Jul 28. Review.

PMID:
26215321
18.

[Albiglutide (Eperzan): a new once-weekly agonist of glucagon-like peptide-1 receptors].

Scheen AJ.

Rev Med Liege. 2015 Apr;70(4):207-14. Review. French.

19.

Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.

Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT.

Diabetes Metab Res Rev. 2016 Nov;32(8):776-790. doi: 10.1002/dmrr.2810. Epub 2016 May 15. Review.

PMID:
27102969
20.

A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes.

Genovese S, Mannucci E, Ceriello A.

Adv Ther. 2017 Aug;34(8):1791-1814. doi: 10.1007/s12325-017-0499-6. Epub 2017 Jul 3. Review.

Supplemental Content

Support Center